Abbott Nutrition
Trial Pipeline
Infant Formula in Infants and Children With Cow's Milk Allergy
NCT06456541
Infants Fed Extensively Hydrolyzed Casein-Based Infant Formulas
NCT04006236
Growth and Tolerance of Infants Fed Milk-Based Infant Formula
NCT03967132
Evaluation of Infants Fed an Extensively Hydrolyzed Infant Formula
NCT03884309
Impact of a Nutrition Quality Improvement Program on Outcomes of Malnourished Patients
NCT03011944
Tolerance of Healthy Infants Fed Infant Formulas
NCT02401217
Gastrointestinal Tolerance of Infant Formula
NCT02322138
A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study
NCT01626742
Evaluation of AN777 on Elderly Subjects During Bed Rest and Recovery
NCT00945581
Tolerance of Healthy Term Infants Fed Infant Formulas #3
NCT00977964
Glucose Tolerance in Healthy Overweight Adults
NCT00974831
Tolerance and Development of Healthy, Term Infants
NCT00465764
Nutritional Study in Preterm Infants
NCT00707837
Nutritional Management of Infants With Chronic Diarrhea
NCT01820494
Soy Formula Feedings in Healthy, Term Infants
NCT02456831
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 3 |
What the Pipeline for Abbott Nutrition Shows
According to the ClinicalTrials.gov registry, Abbott Nutrition is linked to 15 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 7% of the sponsor's indexed portfolio — and 14 are already marked complete, representing roughly 93% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Abbott Nutrition reports 3 late-stage studies (Phase 3 and Phase 4 combined) and 3 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Abbott Nutrition is Gastrointestinal Tolerance with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.